ASH 2020 | Treatment selection and sequencing for multiple myeloma
Niels van de Donk
• 11 Dec 2020
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, outlines the highlights in multiple myeloma presented at ASH 2020. With an increasing number of drugs available, including IMiDs, steroids and antibodies, research into combining or sequencing these treatments is becoming more complex. Dr van de Donk discusses the treatment of patients in their first relapse post-lenalidomide, the management of double-refractory patients, and daratumumab-based and B-cell maturation antigen (BCMA)-targeting treatment strategies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
